Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 51 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
BioKuris from Herstal, company number BE0769454379, closed financial year 2025 with a result of € -1.7 million after tax. For that financial year BioKuris recorded revenue of € 700,235 and equity of € 1.1 million. Compared with financial year 2024, the result moved from € -2.1 million to € -1.7 million. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on May 28, 2026.
€ 1.1 million
▼ 42% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1.7 million
▲ 19 % less loss than in 2024
Profit after tax over the fiscal year.
€ 223,006
▼ 15% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -2.6 million.
People and assets in 2025
1
Average over the fiscal year, from the social balance sheet.
€ 58,897
▲ 234% vs 2024
€ 58,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 600,000
Loans from banks and other lenders, long and short.
€ 711,728
▲ 29% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 8,944
▲ € 7,018 vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 140,000 | € 432,526 | € 512,843 | € 700,235 | ▲ 37% |
| Gross margin | € -933,127 | € -826,431 | € -923,813 | € -511,898 | ▲ € 411,915 |
| Profit after taxes | € -2,019,570 | € -1,854,414 | € -2,076,632 | € -1,678,029 | ▲ € 398,603 |
| Equity | € 4,524,811 | € 3,413,317 | € 1,805,197 | € 1,050,973 | ▼ 42% |
| Total debts | € 2,343,754 | € 3,185,473 | € 4,454,580 | € 4,794,763 | ▲ 8% |
| Cash | € 1,284,283 | € 488,012 | € 262,714 | € 223,006 | ▼ 15% |
| Retained profit | € -2,019,570 | € -3,873,984 | € -5,950,616 | € -2,628,645 | ▲ € 3.3 million |
| Bank debt | € 0 | € 0 | € 600,000 | € 600,000 | |
| Balance sheet total | € 6,868,565 | € 6,598,790 | € 6,259,777 | € 5,845,736 | ▼ 7% |
| Employees (FTE) | - | - | 1 | 1 |
Key figures of BioKuris, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to BioKuris?
What happened at BioKuris in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- INNODE SA stepped down as director. NBB
- SAPRAXIS SA stepped down as director. NBB
- Salvatore MODICA stepped down as director. NBB
- CEMAVI SARL stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 1.7 million. Source: NBB ↗
- KitoZyme SA stepped down as director. NBB
- SAPRAXIS SA became a director. NBB
- KitoZyme SA became a director. NBB
In short
From € 2 million loss in 2022 to € 1.7 million loss in 2025.
A new publication or filing at BioKuris? We notify you, reason included.
Follow BioKurisDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by KitoZyme sa (76%) and Wallonie Entreprendre sa (7%).
Directors
According to the 2025 annual accounts
Managing director · represented by François BLONDEL
Owns 12.2% via KitoZyme sa
Also active at: Wishbone, KiOmed Pharma, ASKLEPIOS Capital
since 2021 · until 2027
Director · represented by Géry Lefebvre
Also active at: C.P. Bourg, A.M.B., Jean Goldschmidt International, Ateliers Pierre Cerfontaine, Floridienne, Fonderies J. Marichal Ketin et Cie, JUNGLING, MEBF +224 more
since 2023 · until 2027
Salvatore MODICA
Director
since 2021 · until 2027
Director · represented by Pierre Desreumaux
since 2021 · until 2027
since 2023 · until 2026
Shareholders
KitoZyme sa · holding of INNODE SA
76%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue de Milmort 680
4040 Herstal
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Certifications & Partners
Hosting & Email
Email provider
Microsoft 365
Hosting
GANDI-AS Domain name registrar - www.gandi.net, FR
Domain
Domain
biokuris.com
Registered
2021-05-26
Registrar
Gandi SAS
Expires
2026-05-26
Website info
Features
Security
Network
Details
- Company number
- 0769.454.379
- VAT number
- BE 0769.454.379
- Registered office
- Rue de Milmort 680, 4040 Herstal
- Names & denominations
- BioKuris
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 8 June 2021
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied